Insights
/
Articles
/

Marketing GLP-1s: What Obesity Changes About the Chronic Disease Playbook

Obesity affects 40.3% of U.S. adults, according to the CDC's most recent survey cycle, and about 11% now report taking a GLP-1 for weight loss, a record in Gallup's July 2026 reading. Such large demand invites broad targeting, but results depend on putting the right message in front of the right consumers and the providers who treat them.

‍

Strategy Should Consider that Demand is Patient-Led

In an early 2025 Omada Health survey of more than 2,000 primary care physicians, doctors estimated that nearly 30% of their patients had asked for a GLP-1 for weight loss. In most categories the physician introduces the therapy, but here the patient often raises it first, which makes DTC a particularly important lever in the exam-room conversation. 

‍

In healthcare marketing, every prescription involves a patient and a prescriber in the same appointment. What differs here is that the patient is particularly likely to start the conversation, and what they have already seen shapes the questions the prescriber is answering. 

‍

Three-quarters of physicians in the same survey said they were more likely to prescribe GLP-1s for weight loss to patients with cardiometabolic comorbidities, so those signals should influence the building of each audience.

‍

Access Is Widening, and Audiences Need to Keep Up

Since July 1, Medicare's GLP-1 Bridge has covered obesity drugs for the first time, at a $50 copay for eligible beneficiaries. Such changes bring new groups of patients into the conversation, and Bridge patients need a physician to complete a prior authorization before coverage starts. An audience built six months ago describes the market prior to this major change.

‍

It’s important to bear in mind that usage is concentrated by age. Gallup found roughly one in six adults aged 40 to 64 reported taking a GLP-1 in late 2025, and Medicare's new coverage pathway adds older adults to the eligible pool.

‍

Prescribing Is Spread Across Care Settings

Primary care providers remain the main prescribers of GLP-1s for weight loss, though an Omada Health survey published in May 2026 found alternate prescribing pathways growing in popularity. A script may therefore come from a clinician other than the PCP most familiar with the patient’s history, like a telehealth provider. An HCP audience for a GLP-1 has to account for both settings, since the prescriber a campaign reaches may not be the one holding the full picture.

‍

Integrated Campaigns Fit GLP-1s Exceptionally Well

Integrated campaigns coordinate HCP and patient messaging so that the people who see condition information and the clinicians who see clinical information overlap. Obesity is a particularly good example of that overlap mirroring how care works: the patient often raises the therapy, and the prescriber decides whether it’s appropriate. Patients can get accessible information on what the therapy involves, while prescribers get the clinical detail and coverage pathways they need to answer.

‍

DeepIntent Helix™ and DeepIntent Cora™ now incorporate payer and formulary signals alongside richer diagnostic data. With Cora, a team can ask which prescribers see a high volume of patients with obesity-related conditions in plans that cover the therapy, then build the matching HCP and patient audiences in the same conversation for brand and agency partners to review together. Script lift then shows whether the two halves of the campaign moved prescribing together.

‍

As GLP-1 adoption expands, marketers need strategies that reflect how treatment decisions actually happen. That means reaching patients and prescribers with relevant information, accounting for evolving access, and connecting both sides of the conversation.

‍